Among the populations most significantly affected by COVID-19 are the elderly and patients with preexisting medical conditions including diabetes, hypertension,
Continue reading »
Home »
Connecting genes to diseases through proteins
Hundreds of connections between different human diseases have been uncovered through their shared origin in our genome by an international
Continue reading »
Upadacitinib Effective and Safe in Atopic Dermatitis at 52 Weeks
Upadacitinib (Rinvoq, AbbVie) in combination with topical corticosteroids is safe and effective for the treatment of moderate to severe atopic
Continue reading »
Vaccinations, masks are best tools against Delta variant
The U.S. is once again experiencing an increase in COVID-19 cases, hospitalizations and deaths due, in part, to the rapid
Continue reading »
Research shows opportunities to improve the accuracy of dispatching pre-hospital critical care
In a retrospective study of trauma patients over 65 years of age attended by KSS, it was found that, although
Continue reading »
Novel agent shows promise in treating the most aggressive type of breast cancer
A unique antibody drug conjugate (ADC), which delivers a high dose of a cancer-killing drug to tumor cells through a
Continue reading »
From scorpion to immunotherapy: Team repurposes nature’s toxin for CAR T
City of Hope scientists have developed and tested the first chimeric antigen receptor (CAR) T cell therapy using chlorotoxin (CLTX),
Continue reading »
Scientists create a renewable source of cancer-fighting T cells
A study by UCLA researchers is the first to demonstrate a technique for coaxing pluripotent stem cells—which can give rise
Continue reading »
Immune response mechanism described for fate determination of T cells
After a pathogen infects the body, the immune system responds with a remarkable—and remarkably complicated—cascade of events. Some immune cells,
Continue reading »
Expansion of circulating tumor-specific T cells after treatment suggested systemic antitumor immunity
The anti-PD1 immunotherapy nivolumab (Opdivo) given prior to surgical resection of stage 1-3 non-small cell lung cancer (NSCLC) was safe
Continue reading »